RS54135B1 - Jedinjenje kao inhibitor puteva prenosa notch signalizacije - Google Patents

Jedinjenje kao inhibitor puteva prenosa notch signalizacije

Info

Publication number
RS54135B1
RS54135B1 RS20150496A RSP20150496A RS54135B1 RS 54135 B1 RS54135 B1 RS 54135B1 RS 20150496 A RS20150496 A RS 20150496A RS P20150496 A RSP20150496 A RS P20150496A RS 54135 B1 RS54135 B1 RS 54135B1
Authority
RS
Serbia
Prior art keywords
cancer
mmol
pharmaceutically acceptable
compound
hydrate
Prior art date
Application number
RS20150496A
Other languages
English (en)
Serbian (sr)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of RS54135B1 publication Critical patent/RS54135B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
RS20150496A 2011-07-27 2012-07-18 Jedinjenje kao inhibitor puteva prenosa notch signalizacije RS54135B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (1)

Publication Number Publication Date
RS54135B1 true RS54135B1 (sr) 2015-12-31

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20150496A RS54135B1 (sr) 2011-07-27 2012-07-18 Jedinjenje kao inhibitor puteva prenosa notch signalizacije

Country Status (36)

Country Link
US (1) US8569286B2 (OSRAM)
EP (1) EP2736920B1 (OSRAM)
JP (1) JP6027110B2 (OSRAM)
KR (1) KR101578309B1 (OSRAM)
CN (1) CN103732612B (OSRAM)
AP (1) AP4080A (OSRAM)
AR (1) AR087107A1 (OSRAM)
AU (1) AU2012287251B2 (OSRAM)
BR (1) BR112014001600B1 (OSRAM)
CA (1) CA2841178C (OSRAM)
CL (1) CL2014000175A1 (OSRAM)
CO (1) CO6862159A2 (OSRAM)
CR (1) CR20140036A (OSRAM)
CY (1) CY1116645T1 (OSRAM)
DK (1) DK2736920T3 (OSRAM)
DO (1) DOP2014000011A (OSRAM)
EA (1) EA023044B1 (OSRAM)
EC (1) ECSP14013179A (OSRAM)
ES (1) ES2544937T3 (OSRAM)
GT (1) GT201400012A (OSRAM)
HR (1) HRP20150771T1 (OSRAM)
HU (1) HUE027534T2 (OSRAM)
IL (1) IL229988A (OSRAM)
JO (1) JO3148B1 (OSRAM)
MA (1) MA35611B1 (OSRAM)
ME (1) ME02171B (OSRAM)
MX (1) MX356536B (OSRAM)
MY (1) MY184303A (OSRAM)
PE (1) PE20141061A1 (OSRAM)
PH (1) PH12014500215B1 (OSRAM)
PL (1) PL2736920T3 (OSRAM)
PT (1) PT2736920E (OSRAM)
RS (1) RS54135B1 (OSRAM)
SI (1) SI2736920T1 (OSRAM)
TW (1) TWI568730B (OSRAM)
WO (1) WO2013016081A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕(notch)路徑傳訊抑制化合物
KR102808827B1 (ko) 2016-02-05 2025-05-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017180385A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
CN109475629A (zh) * 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
EP3552017B1 (en) 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
JP2022504265A (ja) 2018-10-02 2022-01-13 フリークエンシー セラピューティクス インコーポレイテッド 耳治療薬に関する医薬組成物及び方法
TW202103692A (zh) 2019-04-08 2021-02-01 美商頻率醫療公司 用於治療聽力損失之組合物及方法
JP2025503642A (ja) 2022-01-12 2025-02-04 デナリ セラピューティクス インコーポレイテッド (s)-5-ベンジル-n-(5-メチル-4-オキソ-2,3,4,5-テトラヒドロピリド[3,2-b][1,4]オキサゼピン-3-イル)-4h-1,2,4-トリアゾール-3-カルボキサミドの結晶性形態

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951466T3 (da) * 1996-12-23 2009-03-16 Elan Pharm Inc Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
PL378405A1 (pl) 2003-02-04 2006-04-03 F. Hoffmann-La Roche Ag Pochodne malonoamidu jako inhibitory <$Egamma> - sekretazy
KR100834177B1 (ko) 2003-09-09 2008-05-30 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
PL1673347T3 (pl) 2003-10-06 2016-01-29 Hoffmann La Roche Podstawione pochodne dibenzo-azepiny i benzo-diazepiny użyteczne jako inhibitory gamma-sekretazy
MX2008012136A (es) 2006-03-27 2008-10-03 Hoffmann La Roche Derivados de malonamida como inhibidores de gama secretasa.
AU2008209861B2 (en) * 2007-02-02 2012-08-09 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives
CA2710913A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
AU2012287251B2 (en) 2015-05-14
EA201490161A1 (ru) 2014-04-30
PL2736920T3 (pl) 2015-11-30
NZ618891A (en) 2015-12-24
AP2014007362A0 (en) 2014-01-31
AP4080A (en) 2017-03-29
CR20140036A (es) 2014-03-21
JO3148B1 (ar) 2017-09-20
HUE027534T2 (en) 2016-11-28
ES2544937T3 (es) 2015-09-07
CA2841178A1 (en) 2013-01-31
JP2014527042A (ja) 2014-10-09
EP2736920A1 (en) 2014-06-04
WO2013016081A1 (en) 2013-01-31
MA35611B1 (fr) 2014-11-01
MX2014001084A (es) 2014-02-27
DK2736920T3 (en) 2015-07-20
KR20140026624A (ko) 2014-03-05
CY1116645T1 (el) 2017-03-15
PE20141061A1 (es) 2014-09-06
IL229988A (en) 2017-07-31
CL2014000175A1 (es) 2014-08-22
US8569286B2 (en) 2013-10-29
PH12014500215B1 (en) 2018-09-07
MY184303A (en) 2021-03-31
HK1194086A1 (en) 2014-10-10
AR087107A1 (es) 2014-02-12
DOP2014000011A (es) 2014-07-31
US20130029972A1 (en) 2013-01-31
ME02171B (me) 2015-10-20
PT2736920E (pt) 2015-09-16
EP2736920B1 (en) 2015-07-01
CN103732612A (zh) 2014-04-16
JP6027110B2 (ja) 2016-11-16
HRP20150771T1 (hr) 2015-08-28
CO6862159A2 (es) 2014-02-10
EA023044B1 (ru) 2016-04-29
AU2012287251A1 (en) 2014-01-30
SI2736920T1 (sl) 2015-08-31
BR112014001600A2 (pt) 2017-02-21
CN103732612B (zh) 2015-09-23
ECSP14013179A (es) 2014-03-31
TW201315732A (zh) 2013-04-16
PH12014500215A1 (en) 2014-03-17
GT201400012A (es) 2014-07-16
BR112014001600B1 (pt) 2022-09-13
CA2841178C (en) 2016-12-20
KR101578309B1 (ko) 2015-12-16
TWI568730B (zh) 2017-02-01
MX356536B (es) 2018-06-01

Similar Documents

Publication Publication Date Title
RS54135B1 (sr) Jedinjenje kao inhibitor puteva prenosa notch signalizacije
CA3144859C (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
JP6333280B2 (ja) グルタミナーゼ阻害剤およびその使用方法
CA2786834C (en) 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
CN112771053A (zh) 基于生物标志物的治疗组合物
JP6412278B2 (ja) 平滑筋肉腫の標的治療
CN115768757B (zh) Cd206调节剂及其用途和制备方法
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
NZ618891B2 (en) Notch pathway signaling inhibitor compound
HK1194086B (en) Notch pathway signaling inhibitor compound
HK1251166B (en) Targeted treatment of leiomyosarcoma